분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2014-11-15 14:13:56 , Hit : 1186
 AbbVie, Enanta drug shows potential in hep C genotype 4 patients


Tue Nov 11, 2014 10:28am EST

Mon, Nov 10 2014
RPT - INSIGHT-After hep C cure, companies target next big liver disease market
Mon, Nov 10 2014Analysis & OpinionSurprising source offers signs the global ‘war on drugs’ may be ending
Amgen boss makes a prime breakup target
Related TopicsHealth »
(Reuters) - AbbVie Inc said its experimental drug that treats genotype 4 hepatitis C showed high response rates in a mid-stage study in patients who have been considered difficult to treat.

The company is developing the drug with Enanta Pharmaceuticals Inc.

AbbVie said on Tuesday 100 percent of the patients who were given the drug and had failed previous treatment showed high response rates at 12 weeks after the treatment.

Genotype 4 variant of the hepatitis C virus is more frequent in the Middle East and Africa, affecting about 34 million people across the world.

Other drugmakers such as Merck & Co Inc, Gilead Sciences Inc and Achillion Pharmaceuticals Inc have been working on their own hepatitis C candidates with the aim of reducing treatment time from the current 8-12 weeks.

J.P. Morgan Securities analysts said in a note that AbbVie's treatment duration is unlikely to move into the four-six week range.

However, they continue to expect AbbVie to capture at least 20 percent of the $15-billion-plus hepatitis C market next year.

AbbVie also presented data from another mid-stage study where patients infected with both genotype 1 hepatitis C and HIV viruses showed response rates of 93.5 percent and 90.6 percent after 12 and 24 weeks post-treatment, respectively.

AbbVie's treatments are co-administered with Ribavirin, a commonly used drug in the treatment of hepatitis C which comes with a harsh safety profile.

Shares of AbbVie were up 0.11 percent at $63.72 and those of Enanta were down 0.20 percent at $44.05 in early trading.


(Reporting by Amrutha Penumudi in Bangalore)







987   인간과 생쥐 유전체의 유사성과 차이점  이성욱 2014/11/25 1923
986   Cost to Develop a Drug More Than Doubles to $2.56 Billion  이성욱 2014/11/21 1128
985   세균과 싸우도록 자극하면, 바이러스까지도 물리치는 세포  이성욱 2014/11/20 1492
984   Gilead wins European approval of next-generation hepatitis C drug  이성욱 2014/11/20 1159
983   [바이오토픽] 표준 인간 게놈지도의 갭을 메워라: 플래티넘 게놈지도 탄생  이성욱 2014/11/19 1595
982   종양 내에서 T 세포 면역에 핵심적인 항원제시 세포  이성욱 2014/11/17 1659
  AbbVie, Enanta drug shows potential in hep C genotype 4 patients  이성욱 2014/11/15 1186
980   Gilead hepatitis C drug highly effective in cirrhosis patients  이성욱 2014/11/14 1067
979   새로운 HIV/AIDS 치료법 개발  이성욱 2014/11/14 1468
978   간 이식 환자들의 C형 간염을 완치시킨 새로운 치료법  이성욱 2014/11/14 1665
977   간 이식 환자들의 C형 간염에 효과적인 병용 요법  이성욱 2014/11/13 1608
976   J&J Wins U.S. Approval for Hepatitis C Combo With Gilead  이성욱 2014/11/07 1523
975   에볼라에 대한 반응과 유전적 요인  이성욱 2014/11/04 1279
974   실험실에서 만든 인공위장  이성욱 2014/11/04 1222
973   거울이미지 RNA효소와 생명이 기원  이성욱 2014/11/03 1493
972   어떻게 복잡한 생명은 진화했는가?  이성욱 2014/10/31 1601
971   인간 녹아웃을 연구하는 유전학자들  이성욱 2014/10/31 1563
970   As the RNA World Turns (Either Way, with Cross-Chiral Enzyme)  이성욱 2014/10/31 1348
969   암의 우군-엑소좀(exosome)  이성욱 2014/10/29 2788
968   이웃의 정상세포를 감염시키는 암세포  이성욱 2014/10/27 1464

[이전 10개] [1]..[11][12][13][14] 15 [16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN